Literature DB >> 18723960

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections.

Ami Y Varaiya1, Jyotsana D Dogra, Manasi H Kulkarni, Pallavi N Bhalekar.   

Abstract

AIMS: Diabetic foot lesions are a major medical, social, and economic problem and are the leading cause of hospitalization for patients with diabetes, worldwide. ESBL-producing bacteria may not be detectable by routine disc diffusion susceptibility test, leading to inappropriate use of antibiotics and treatment failure. There is not much information on ESBL-producing organisms causing diabetic foot infection. An attempt was therefore made to study the ESBL-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot patients with type 2 diabetes mellitus.
MATERIALS AND METHODS: A total of 134 isolates of E. coli and K. pneumoniae were obtained from tissue, pus swab, and wound swab samples from diabetic foot ulcers submitted for routine microbiological analysis during the period January to December 2005 from patients with diabetic foot infections who had type 2 diabetes mellitus, attending S. L. Raheja Hospital. The above isolates were tested for antimicrobial susceptibility by disc diffusion technique according to clinical and laboratory standards institute (CLSI) guidelines. The screening for ESBL production was done by phenotypic confirmatory test using ceftazidime disc in the presence and absence of clavulanic acid as recommended by CLSI.
RESULTS: Among the 134 isolates, 54 (40.29%) were E. coli and 80 (59.70%) were K. pneumoniae; among which, ESBL production was detected in 31 (23.13%) isolates. Of these 31, 15 (48.38%) were E. coli and 16 (51.61%) were K. pneumoniae. All the ESBL-producing isolates were found to be 100% sensitive to carbapenem (imipenem and meropenem). Mortality was found to be 3.22%, the cause of death being septicemia leading to multiple organ failure.
CONCLUSIONS: The prevalence of ESBLs among members of Enterobacteriaceae constitutes a serious threat to the current beta-lactam therapy, leading to treatment failure and consequent escalation of costs. There is an urgent need to emphasize rational use of drugs to minimize the misuse of available antimicrobials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723960     DOI: 10.4103/0377-4929.42513

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  5 in total

1.  The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them.

Authors:  Bhaskar Thakuria; Kingshuk Lahon
Journal:  J Clin Diagn Res       Date:  2013-06-01

2.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

3.  Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.

Authors:  Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Po-Ren Hsueh; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

4.  Oestrogen promotes healing in a bacterial LPS model of delayed cutaneous wound repair.

Authors:  Rachel Crompton; Helen Williams; David Ansell; Laura Campbell; Kirsty Holden; Sheena Cruickshank; Matthew J Hardman
Journal:  Lab Invest       Date:  2016-02-08       Impact factor: 5.662

5.  A Multicenter Study of Beta-Lactamase Resistant Escherichia coli and Klebsiella pneumoniae Reveals High Level Chromosome Mediated Extended Spectrum β Lactamase Resistance in Ogun State, Nigeria.

Authors:  Folasoge A Adeyankinnu; Babatunde O Motayo; Akinniyi Akinduti; John Akinbo; Joseph I Ogiogwa; Bukola W Aboderin; R A Agunlejika
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.